AACR 2021 | Areas of unmet need for patients with advanced UC
Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, outlines areas of unmet need for patients with advanced urothelial carcinoma (UC) including understanding mechanisms of resistance and lack of response in patients treated with immune checkpoint blockade. Dr Plimack also highlights the importance of identifying treatment regimens with a more tolerable safety profile, especially within the metastatic setting. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Elizabeth Plimack, MD, MS, has participated in consultancy work, scientific advisory boards and or data safety monitoring with Aveo, BMS, Calithera, Genentech, Janssen, MEI Pharma, Merck, Pfizer, Seattle Genetics, AstraZeneca and Infinity Pharma; has received honoraria from Clinical Care Options, Creative Educational Concepts, CUA, JADPRO, PER, Research to Practice, Total CME and The Hawaii Society of Clinical Oncology; and has received grants for clinical research from Astellas, BMS, Genentech and Merck.
